Chronic hepatitis B virus infection and fibrosis: novel non-invasive approaches for diagnosis and risk stratification(91 views) Stalla F, Armandi A, Marinoni C, Fagoonee S, Pellicano R, Caviglia GP
Department of Medical Sciences, University of Turin, Turin, Italy.
Institute of Biostructure and Bioimaging, National Research Council, Molecular Biotechnology Center, Torino, Italy.
Division of Gastroenterology, Molinette Hospital - Città della Salute e della Scienza di Torino, Turin, Italy.
References: Not available.
Chronic hepatitis B virus infection and fibrosis: novel non-invasive approaches for diagnosis and risk stratification
Despite the availability of an effective vaccination, chronic hepatitis B virus (HBV) infection is still a major health concern worldwide. Chronic HBV infection can lead to fibrosis accumulation and overtime to cirrhosis, the principal risk factor for liver failure and hepatocellular carcinoma development. Liver biopsy is still considered the gold standard for fibrosis assessment, even though it is invasive and not exempt of complications. Overtime, several non-invasive methods for the detection of liver fibrosis have been developed and gradually introduced into clinical practice. However, their main limitation is the poor performance for the detection of intermediate stages of fibrosis. Finally, novel serological biomarkers, polygenic risk scores and imaging methods have been proposed in last years as novel promising tools to correctly identify the degree of liver fibrosis and to monitor liver disease progression. In this narrative review, we provide an overview on the novel non-invasive approaches for the evaluation of liver fibrosis and risk stratification of patients with chronic hepatitis B.
Chronic hepatitis B virus infection and fibrosis: novel non-invasive approaches for diagnosis and risk stratification